-
Dec 4, 2024 | 
nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more
AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
-
Dec 4, 2024 | nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more
AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
-
Aug 28, 2024 | 
targetedonc.com | Nausheen Ahmed
A recent study examined the real-world experience of patients receiving CD19-directed chimeric antigen receptor (CAR) T-cell therapies for B-cell non-Hodgkin lymphoma. The primary focus was on the occurrence and duration of side effects like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
-
Aug 27, 2024 | 
onlinelibrary.wiley.com | Utkarsh Goel |Danai Dima |James Davis |Nausheen Ahmed
What is the new aspect of your work? This multicenter retrospective study represents the largest case series describing the use of standard of care chimeric antigen receptor (CAR) T-cell therapy in patients with AL amyloidosis and concurrent relapsed/refractory multiple myeloma. What is the central finding of your work?
-
Aug 15, 2024 | 
targetedonc.com | Nausheen Ahmed
CAR T-cell therapies have shown remarkable efficacy in treating hematologic malignancies but carry risks. Current guidelines require close patient monitoring for 4 weeks post-treatment. A study of 475 patients found that serious side effects like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are extremely rare after 2 weeks.
-
Jul 31, 2024 | 
cancernetwork.com | Nausheen Ahmed
Infection prevention and management is an area that, if addressed, would improve outcomes in patients receiving CAR T-cell therapy, according to Nausheen Ahmed, MD, lead author of a Blood Advances retrospective study. CancerNetwork® spoke with Ahmed, an associate professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center.
-
Jul 31, 2024 | 
cancernetwork.com | Nausheen Ahmed
CancerNetwork® spoke with Nausheen Ahmed, MD, an associate professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center. Ahmed addressed retrospective findings that CAR T-cell therapy may lead to secondary malignancies, and if these findings would influence the use of these agents.
-
Jul 30, 2024 | 
cancernetwork.com | Nausheen Ahmed
CAR T-cell therapy requires a greater investment in a patient’s time and may carry financial and physical burdens from the onset of treatment to weeks upon its completion, according to Nausheen Ahmed, MD. CancerNetwork® spoke with Nausheen Ahmed, MD, an associate professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center.
-
Jul 29, 2024 | 
cancernetwork.com | Nausheen Ahmed
In a conversation with CancerNetwork®, Nausheen Ahmed, MD, spoke about optimizing monitoring strategies for patients with B-cell non-Hodgkin lymphoma who undergo treatment with CAR T-cell therapy.
-
Jul 7, 2024 | 
nature.com | Mazyar Shadman |Madiha Iqbal |Nausheen Ahmed |Peter A. Riedell |Natalie Grover |Nilanjan Ghosh | +8 more
AbstractIn patients with relapsed DLBCL in complete remission (CR), autologous hematopoietic cell transplantation (auto-HCT) and CAR-T therapy are both effective, but it is unknown which modality provides superior outcomes. We compared the efficacy of auto-HCT vs. CAR-T in patients with DLBCL in a CR. A retrospective observational study comparing auto-HCT (2015–2021) vs. CAR-T (2018–2021) using the Center for International Blood & Marrow Transplant Research registry.
